Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

Mamoru Watanabe; Toshifumi Hibi; Nael M Mostafa; Jingdong Chao; Vipin Arora; Anne Camez; Joel Petersson; Roopal Thakkar

首页> 外文期刊>Journal of Crohn’s & colitis >Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

【24h】

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

机译：阿达木单抗在日本中重度克罗恩病患者中的长期安全性和有效性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Adalimumab is effective for maintaining long-term clinical remission in Japanese patients with moderate to severe Crohn's disease (NCT00445432).

机译：阿达木单抗可有效维持中度至严重克罗恩病（NCT00445432）的日本患者的长期临床缓解。

著录项

来源
《Journal of Crohn’s & colitis》 |2014年第11期|共10页
作者
Mamoru Watanabe; Toshifumi Hibi; Nael M Mostafa; Jingdong Chao; Vipin Arora; Anne Camez; Joel Petersson; Roopal Thakkar;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. [J] . Mamoru Watanabe, Toshifumi Hibi, Nael M Mostafa, Journal of Crohn’s & colitis . 2014,第11期

机译：阿达木单抗在日本中重度克罗恩病患者中的长期安全性和有效性。
2. Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial [J] . Panaccione Remo, Loftus Edward V, Binion David, ISRN Hypertension . 2011,第8期

机译：阿达木单抗在加拿大中度至严重克罗恩病患者中的疗效和安全性：阿达木单抗在加拿大患有严重克罗恩DiseaSe（ACCESS）试验的受试者中的结果
3. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar Bl 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) [J] . Stanley B. Cohen, Niklas Czeloth, Eric Lee, Expert opinion on biological therapy . 2019,第7a12期

机译：具有中度至严重活性的类风湿性关节炎的患者Adalimalab BioSimilar BL 695501和Adalimalab参考产物的长期安全性，疗效和免疫原性：来自第3B期扩展研究的结果（Voltaire-Reext）
4. SAFETY AND EFFICACY OF PCV2 INACTIVATED VACCINE IN A JAPANESE COMMERCIAL FARM [C] . Kenichi Sato, Kyoko Hirama, Yoichi Takahagi, Congress of the International Pig Veterinary Society . 2008

机译：PCV2灭活疫苗在日本商业农场中的安全性和有效性
5. The effect of anticholinergic burden on functional outcomes in patients with moderate to severe Alzheimer's disease. [D] . Dharia, Sheetal Prabodh. 2010

机译：抗胆碱能负担对中度至重度阿尔茨海默氏病患者功能结局的影响。
6. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial [O] . Remo Panaccione, Edward V Loftus Jr, David Binion, 2011

机译：阿达木单抗在加拿大中度至严重克罗恩病患者中的疗效和安全性：阿达木单抗在加拿大受试者中的应用（对重度克罗恩DiseaSe（ACCESS）进行ModErate的试验）
7. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease [O] . Watanabe Mamoru, Hibi Toshifumi, Mostafa Nael M., 2014

机译：阿达木单抗在日本中重度克罗恩病患者中的长期安全性和有效性

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

摘要

著录项

相似文献

相关主题

期刊订阅